Covid-19 Impact on Neurodegenerative Disease Market, Global Research Reports 2020-2021

2 Global Neurodegenerative Disease Quarterly Market Size Analysis

• 2.1 Neurodegenerative Disease Business Impact Assessment - COVID-19
  • 2.1.1 Global Neurodegenerative Disease Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Neurodegenerative Disease Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Neurodegenerative Disease Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Neurodegenerative Disease Headquarters and Area Served
• 3.3 Date of Key Players Enter into Neurodegenerative Disease Market
• 3.4 Key Players Neurodegenerative Disease Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Neurodegenerative Disease Segments, By Type

• 4.1 Introduction
  • 1.4.1 NMDA
  • 1.4.2 SSRIs
  • 1.4.3 Dopamine Inhibitors
• 4.2 By Type, Global Neurodegenerative Disease Market Size, 2019-2021

5 Impact of Covid-19 on Neurodegenerative Disease Segments, By Application

• 5.1 Overview
  • 5.5.1 Parkinson’s Disease
  • 5.5.2 Huntington Disease
  • 5.5.3 Amyotrophic Lateral Sclerosis
  • 5.5.4 Alzheimer’s Disease
• 5.2 By Application, Global Neurodegenerative Disease Market Size, 2019-2021
  • 5.2.1 By Application, Global Neurodegenerative Disease Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Novartis
  • 7.1.1 Novartis Business Overview
  • 7.1.2 Novartis Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.1.3 Novartis Neurodegenerative Disease Product Introduction
  • 7.1.4 Novartis Response to COVID-19 and Related Developments
• 7.2 Pfizer
  • 7.2.1 Pfizer Business Overview
  • 7.2.2 Pfizer Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.2.3 Pfizer Neurodegenerative Disease Product Introduction
  • 7.2.4 Pfizer Response to COVID-19 and Related Developments
• 7.3 Merck Serono
  • 7.3.1 Merck Serono Business Overview
  • 7.3.2 Merck Serono Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.3.3 Merck Serono Neurodegenerative Disease Product Introduction
  • 7.3.4 Merck Serono Response to COVID-19 and Related Developments
• 7.4 Biogen Idec
  • 7.4.1 Biogen Idec Business Overview
  • 7.4.2 Biogen Idec Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.4.3 Biogen Idec Neurodegenerative Disease Product Introduction
  • 7.4.4 Biogen Idec Response to COVID-19 and Related Developments
• 7.5 TEVA
  • 7.5.1 TEVA Business Overview
  • 7.5.2 TEVA Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.5.3 TEVA Neurodegenerative Disease Product Introduction
  • 7.5.4 TEVA Response to COVID-19 and Related Developments
• 7.6 UCB
  • 7.6.1 UCB Business Overview
  • 7.6.2 UCB Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.6.3 UCB Neurodegenerative Disease Product Introduction
  • 7.6.4 UCB Response to COVID-19 and Related Developments
• 7.7 Boehringer Ingelheim
  • 7.7.1 Boehringer Ingelheim Business Overview
  • 7.7.2 Boehringer Ingelheim Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.7.3 Boehringer Ingelheim Neurodegenerative Disease Product Introduction
  • 7.7.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
• 7.8 Sanofi
  • 7.8.1 Sanofi Business Overview
  • 7.8.2 Sanofi Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.8.3 Sanofi Neurodegenerative Disease Product Introduction
  • 7.8.4 Sanofi Response to COVID-19 and Related Developments
• 7.9 GlaxoSmithKline
  • 7.9.1 GlaxoSmithKline Business Overview
  • 7.9.2 GlaxoSmithKline Neurodegenerative Disease Quarterly Revenue, 2020
  • 7.9.3 GlaxoSmithKline Neurodegenerative Disease Product Introduction
  • 7.9.4 GlaxoSmithKline Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US